Cue Biopharma, Inc. (CUE) stock forecast & analysis
4.50
NasdaqCM · USDDelayed by 15 minutes
Down: -0.26, -5.5%
4.30Down: -0.20, -4.4%
1 analysis
Latest analysis: · verdict locked
- Open
- 4.55
- Previous close
- 4.76
- Day range
- 3.85 – 5.16
- 52-week range
- 2.83 – 45.50
- Volume (shares)
- 2.06M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 8.36M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- Not available
- Market cap
- 37.62M
Market Scanner’s AI analysis of Cue Biopharma, Inc. (CUE), updated November 2026: Cue Biopharma's recent analyses focused on a dramatic price collapse and the lack of substantive news flow.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Cue Biopharma, Inc. (CUE) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Cue Biopharma's recent analyses focused on a dramatic price collapse and the lack of substantive news flow.
Recent analyses for Cue Biopharma (CUE) covered a significant price decline from the $28–38 range to a recent close of $4.76, falling through major technical levels. The stock experienced a sharp rebound on high volume, but this was not seen as an established base. The news flow was limited, with only one relevant company-specific event being the Q3 2026 results announcement, though details on financials or pipeline milestones were not available.
CUE news & sentiment
News flow for Cue Biopharma was sparse, with limited company-specific events and a lack of detailed financial information. Social media discussion was not covered in the provided notes.
CUE technical picture
CUE experienced a sharp price collapse, falling through all major technical levels and trading significantly below its 50-day and 200-day SMAs. A recent rebound occurred on high volume, but this was not characterized as an established base.
Fundamentals
The analysis covered Cue Biopharma's market capitalization and share price relative to its 52-week range and moving averages, noting a significant decline from its highs. No information was provided on revenue, margins, cash flow, or capital intensity.
Factors discussed — upside
- Sharp rebound on high volume from a one-day low.
Factors discussed — risks
- Price collapse from the $28–38 range to $4.76.
- Stock has fallen through every major technical level.
- Price is significantly below 50-day and 200-day SMAs.
- Lack of substantive news flow and financial details from Q3 results.
- Price action
- Technical levels
- News flow
- Financials
Summary updated .
CUE technical indicators
Common technical indicators for CUE, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 22.14 | Price below |
| 10-day exponential moving average | 11.55 | Price below |
| Relative strength index (14-day) | 25.08 | Oversold |
| MACD line (12/26/9) | -3.9485 | Below its signal line |
| Bollinger bands (20-day, 2σ) | 5.51 – 27.80 | Price below the lower band |
Analyses
Recent CUE.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-11-19 CUE.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for Cue Biopharma, Inc.?
- The recent analyses noted a sharp rebound in price on high volume from a one-day low as a potential upside driver.
- What are the risks for Cue Biopharma, Inc.?
- Risks discussed included the stock's dramatic price collapse through major technical levels, its significant distance below key moving averages, and a lack of substantive news flow or financial details from recent earnings reports.
- Is Cue Biopharma, Inc. bullish or bearish?
- Recent AI analyses of Cue Biopharma, Inc. examined factors on both sides. Discussed upside: The recent analyses noted a sharp rebound in price on high volume from a one-day low as a potential upside driver. Discussed risks: Risks discussed included the stock's dramatic price collapse through major technical levels, its significant distance below key moving averages, and a lack of substantive news flow or financial details from recent earnings reports. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Cue Biopharma, Inc.?
- News flow for Cue Biopharma was sparse, with limited company-specific events and a lack of detailed financial information. Social media discussion was not covered in the provided notes.
- How does Market Scanner analyse Cue Biopharma, Inc.?
- Every analysis of Cue Biopharma, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Cue Biopharma, Inc.?
The recent analyses noted a sharp rebound in price on high volume from a one-day low as a potential upside driver.
What are the risks for Cue Biopharma, Inc.?
Risks discussed included the stock's dramatic price collapse through major technical levels, its significant distance below key moving averages, and a lack of substantive news flow or financial details from recent earnings reports.
Is Cue Biopharma, Inc. bullish or bearish?
Recent AI analyses of Cue Biopharma, Inc. examined factors on both sides. Discussed upside: The recent analyses noted a sharp rebound in price on high volume from a one-day low as a potential upside driver. Discussed risks: Risks discussed included the stock's dramatic price collapse through major technical levels, its significant distance below key moving averages, and a lack of substantive news flow or financial details from recent earnings reports. These are descriptive observations, not a recommendation.
What is the latest sentiment on Cue Biopharma, Inc.?
News flow for Cue Biopharma was sparse, with limited company-specific events and a lack of detailed financial information. Social media discussion was not covered in the provided notes.
How does Market Scanner analyse Cue Biopharma, Inc.?
Every analysis of Cue Biopharma, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- claude-medium-v2
Run a fresh CUE.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.